Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.

<h4>Background</h4>Visceral leishmaniasis (VL) is one of the most neglected tropical infectious diseases. It is fatal if left untreated. The objective of this study was to assess the efficacy and safety of 17-day injections of combined regimen of sodium stibogluconate and paromomycin (SS...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aschalew Tamiru, Rezika Mohammed, Saba Atnafu, Girmay Medhin, Asrat Hailu
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/f95ac388400044ab8793649b60e58e03
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f95ac388400044ab8793649b60e58e03
record_format	dspace
spelling	oai:doaj.org-article:f95ac388400044ab8793649b60e58e032021-12-02T20:24:14ZEfficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.1935-27271935-273510.1371/journal.pntd.0009713https://doaj.org/article/f95ac388400044ab8793649b60e58e032021-08-01T00:00:00Zhttps://doi.org/10.1371/journal.pntd.0009713https://doaj.org/toc/1935-2727https://doaj.org/toc/1935-2735<h4>Background</h4>Visceral leishmaniasis (VL) is one of the most neglected tropical infectious diseases. It is fatal if left untreated. The objective of this study was to assess the efficacy and safety of 17-day injections of combined regimen of sodium stibogluconate and paromomycin (SSG/PM) in HIV-negative VL patients.<h4>Methods</h4>A retrospective analysis of medical records of VL patients treated in the University of Gondar Hospital during period 2012-2019 was carried out.<h4>Results</h4>A total of 2836 patients were treated for VL from 2012 to 2019. Of these 1233 were treated with SSG-PM, and 1000 of them were included in the study. Initial cure was achieved in 922 (92.2%) patients. The frequency of treatment failure, treatment interruptions, default and deaths respectively were 30 (3%), 20 (2%), 13 (1.3%) and 15 (1.5%). Among 280 patients who completed 6-month follow up, the final cure was 93.9% (263/280), 4 (1.4%) relapsed and 13 (4.6%) developed post-kala-azar dermal leishmaniasis (PKDL). The most common adverse events (AEs) were raised liver transaminases (35.1%; 351 patients), injection site pain (29.1%, 291 patients) and raised serum alpha-amylase (29.1%, 291 patients). Factors associated with poor treatment outcomes were sepsis, pneumonia, and adverse events.<h4>Conclusion</h4>A combination of SSG at 20mg/kg with upper daily maximum dose of 850mg and PM was effective for achieving initial cure at end of treatment and safe for treatment of HIV negative VL patients in northwestern Ethiopia. Our data are consistent with previous reports and confirms effectiveness of SSG/PM treatment regimen in the Eastern African countries. Efficacy at 6-months (93.9%) was estimated on data derived from patients who completed follow up and needs to be interrogated by future studies.Aschalew TamiruRezika MohammedSaba AtnafuGirmay MedhinAsrat HailuPublic Library of Science (PLoS)articleArctic medicine. Tropical medicineRC955-962Public aspects of medicineRA1-1270ENPLoS Neglected Tropical Diseases, Vol 15, Iss 8, p e0009713 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270
spellingShingle	Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Aschalew Tamiru Rezika Mohammed Saba Atnafu Girmay Medhin Asrat Hailu Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
description	<h4>Background</h4>Visceral leishmaniasis (VL) is one of the most neglected tropical infectious diseases. It is fatal if left untreated. The objective of this study was to assess the efficacy and safety of 17-day injections of combined regimen of sodium stibogluconate and paromomycin (SSG/PM) in HIV-negative VL patients.<h4>Methods</h4>A retrospective analysis of medical records of VL patients treated in the University of Gondar Hospital during period 2012-2019 was carried out.<h4>Results</h4>A total of 2836 patients were treated for VL from 2012 to 2019. Of these 1233 were treated with SSG-PM, and 1000 of them were included in the study. Initial cure was achieved in 922 (92.2%) patients. The frequency of treatment failure, treatment interruptions, default and deaths respectively were 30 (3%), 20 (2%), 13 (1.3%) and 15 (1.5%). Among 280 patients who completed 6-month follow up, the final cure was 93.9% (263/280), 4 (1.4%) relapsed and 13 (4.6%) developed post-kala-azar dermal leishmaniasis (PKDL). The most common adverse events (AEs) were raised liver transaminases (35.1%; 351 patients), injection site pain (29.1%, 291 patients) and raised serum alpha-amylase (29.1%, 291 patients). Factors associated with poor treatment outcomes were sepsis, pneumonia, and adverse events.<h4>Conclusion</h4>A combination of SSG at 20mg/kg with upper daily maximum dose of 850mg and PM was effective for achieving initial cure at end of treatment and safe for treatment of HIV negative VL patients in northwestern Ethiopia. Our data are consistent with previous reports and confirms effectiveness of SSG/PM treatment regimen in the Eastern African countries. Efficacy at 6-months (93.9%) was estimated on data derived from patients who completed follow up and needs to be interrogated by future studies.
format	article
author	Aschalew Tamiru Rezika Mohammed Saba Atnafu Girmay Medhin Asrat Hailu
author_facet	Aschalew Tamiru Rezika Mohammed Saba Atnafu Girmay Medhin Asrat Hailu
author_sort	Aschalew Tamiru
title	Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
title_short	Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
title_full	Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
title_fullStr	Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
title_full_unstemmed	Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
title_sort	efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and paromomycin 15mg/kg/day in hiv negative visceral leishmaniasis patients. a retrospective study, northwest ethiopia.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/f95ac388400044ab8793649b60e58e03
work_keys_str_mv	AT aschalewtamiru efficacyandsafetyofacombinedtreatmentofsodiumstibogluconateat20mgkgdaywithuppermaximumdailydoselimitof850mgandparomomycin15mgkgdayinhivnegativevisceralleishmaniasispatientsaretrospectivestudynorthwestethiopia AT rezikamohammed efficacyandsafetyofacombinedtreatmentofsodiumstibogluconateat20mgkgdaywithuppermaximumdailydoselimitof850mgandparomomycin15mgkgdayinhivnegativevisceralleishmaniasispatientsaretrospectivestudynorthwestethiopia AT sabaatnafu efficacyandsafetyofacombinedtreatmentofsodiumstibogluconateat20mgkgdaywithuppermaximumdailydoselimitof850mgandparomomycin15mgkgdayinhivnegativevisceralleishmaniasispatientsaretrospectivestudynorthwestethiopia AT girmaymedhin efficacyandsafetyofacombinedtreatmentofsodiumstibogluconateat20mgkgdaywithuppermaximumdailydoselimitof850mgandparomomycin15mgkgdayinhivnegativevisceralleishmaniasispatientsaretrospectivestudynorthwestethiopia AT asrathailu efficacyandsafetyofacombinedtreatmentofsodiumstibogluconateat20mgkgdaywithuppermaximumdailydoselimitof850mgandparomomycin15mgkgdayinhivnegativevisceralleishmaniasispatientsaretrospectivestudynorthwestethiopia
_version_	1718374085907447808

Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.

Ejemplares similares